$HEAR

HeartBeam, Inc. reported its Q4 2025 earnings, showing stronger than expected revenue growth driven by the successful launch of its new cardiac monitoring technology. The company also revealed plans to expand its product line, aiming for additional market penetration in the healthcare sector. Analysts noted improved gross margins, which are expected to enhance profitability. However, competition in the cardiac diagnostics market remains fierce, affecting investor sentiment. Overall, HeartBeam appears well-positioned for long-term growth despite short-term challenges.